QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
NASDAQ:HZNP

Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

$110.00
+0.21 (+0.19%)
(As of 02/3/2023 10:32 AM ET)
Add
Compare
Today's Range
$109.75
$110.26
50-Day Range
$78.00
$113.80
52-Week Range
$57.84
$117.49
Volume
219,857 shs
Average Volume
3.63 million shs
Market Capitalization
$24.93 billion
P/E Ratio
45.08
Dividend Yield
N/A
Price Target
$111.42

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
1.3% Upside
$111.42 Price Target
Short Interest
Healthy
2.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.62mentions of Horizon Therapeutics Public in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$11.29 M Sold Last Quarter
Proj. Earnings Growth
28.37%
From $4.23 to $5.43 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

98th out of 1,029 stocks

Pharmaceutical Preparations Industry

41st out of 501 stocks

HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

Rule 15 (c) Announcement – Horizon Therapeutics plc
Biotech Stock Alert
Read Small Pharma's depression clinical trial results.
Rule 17 (b) Announcement – Horizon Therapeutics plc
Rule 2.12 Announcement – Horizon Therapeutics plc
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
These 2 Nasdaq Stocks Are Soaring on Merger News
Horizon Therapeutics Stock Jumps on Amgen Deal News
Amgen to buy Horizon Therapeutics for $28 billion cash
Why Horizon Therapeutics Stock Is Soaring Today
Amgen to acquire Horizon Therapeutics for $27.8 billion
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
11/03/2021
Today
2/03/2023
Next Earnings (Confirmed)
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
1,890
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$111.42
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+1.3%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$534.49 million
Pretax Margin
15.77%

Debt

Sales & Book Value

Annual Sales
$3.23 billion
Cash Flow
$6.41 per share
Book Value
$20.60 per share

Miscellaneous

Free Float
220,955,000
Market Cap
$24.93 billion
Optionable
Optionable
Beta
1.15

Social Links


Key Executives

  • Timothy P. WalbertTimothy P. Walbert
    Chairman, President & Chief Executive Officer
  • Aaron L. Cox
    Chief Financial Officer & Executive Vice President
  • Jeffrey W. ShermanJeffrey W. Sherman
    Chief Medical Officer & Executive Vice President
  • Jeffrey D. Kent
    Executive VP-Medical Affairs & Outcomes Research
  • Michael A. DesJardinMichael A. DesJardin
    Executive VP-Technical Operations & Quality













HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2023?

11 brokerages have issued 1-year price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's share price to reach $111.42 in the next year. This suggests a possible upside of 1.3% from the stock's current price.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2023?

Horizon Therapeutics Public's stock was trading at $113.80 on January 1st, 2023. Since then, HZNP shares have decreased by 3.4% and is now trading at $109.98.
View the best growth stocks for 2023 here
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.54 by $0.21. The biopharmaceutical company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $979.49 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 24.59% and a net margin of 15.51%. The firm's revenue for the quarter was up 62.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.74 EPS.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.59 billion-$3.61 billion, compared to the consensus revenue estimate of $3.56 billion.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.58%), Bank of Montreal Can (0.36%), Strs Ohio (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Allspring Global Investments Holdings LLC (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $109.98.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $24.92 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $2.44 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 2/3/2023 by MarketBeat.com Staff